Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40QEZ | ISIN: US59564R8079 | Ticker-Symbol: 5MP1
NASDAQ
06.06.25 | 16:34
1,150 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
BIODEXA PHARMACEUTICALS PLC ADR Chart 1 Jahr
5-Tage-Chart
BIODEXA PHARMACEUTICALS PLC ADR 5-Tage-Chart

Aktuelle News zur BIODEXA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiBiodexa Pharmaceuticals PLC: Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes94June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), a clinical stage...
► Artikel lesen
30.05.Biodexa Pharmaceuticals PLC: Shareholder Update392May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline...
► Artikel lesen
30.05.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer2
22.05.Biodexa Pharmaceuticals PLC (";Biodexa" or the "Company") Notice of General Meeting1
BIODEXA PHARMACEUTICALS Aktie jetzt für 0€ handeln
22.05.Biodexa sichert zusätzliche 3 Mio. US-Dollar für Krebsmedikamenten-Studie1
22.05.Biodexa secures additional $3M for cancer drug trial1
22.05.Biodexa Pharmaceuticals PLC: Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M112May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M...
► Artikel lesen
22.05.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer1
13.05.EC grants orphan drug status to Biodexa's oral FAP treatment1
12.05.Biodexa Pharmaceuticals: European Commission Grants Orphan Drug Designation For ERapa2
12.05.Biodexa gains orphan drug status in EU for colon disease treatment1
12.05.Biodexa Pharmaceuticals PLC: Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP296May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted...
► Artikel lesen
12.05.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer2
02.05.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer2
02.05.Biodexa Pharmaceuticals PLC: Result of General Meeting106May 2, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Result of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline...
► Artikel lesen
11.04.Biodexa Pharmaceuticals Plc - 20-F, Annual and transition report of foreign private issuers1
11.04.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer1
11.04.Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2024199April 11, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals...
► Artikel lesen
19.03.Biodexa Pharmaceuticals PLC: With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter563CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the...
► Artikel lesen
10.03.Biodexa erhält FDA-Zustimmung für Phase-3-Studie von eRapa bei FAP4
Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1